ERBB2 and neoplasm: Taken together, we have presented here that the engineered destabilized 3'UTR ERBB2-30 delivered by IO nanocages inhibited the drug-resistant EGFR T790M NSCLC with 50% complete tumor lysis, 60% inhibition of ERBB2 protein, 50% therapeutic inhibition of tumor, and 80% reduction of malignant cells.